Trial Discontinued in Cholesterol Drug Evacetrapib After it Fails to Reduce Major Adverse Cardiovascular Events
A large Phase 3 clinical trial of the cholesterol drug evacetrapib was discontinued after an analysis showed it did not reduce the rates of major adverse cardiovascular events, despite lowering “bad” cholesterol levels and ... Read more